萨沃利提尼布:对癌症的有希望的向剂
Tae Seung Lee1, Jun Yeol Kim1, Myeong Hwan Lee1
1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
萨沃利提尼布有效治疗具有MET突变的非小细胞肺癌 (NSCLC). 本综述探讨了其在NSCLC中的疗效以及在胰腺癌等其他胃肠道癌症中的潜在用途.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 萨沃利提尼布是一种选择性的MET氨酸激酶抑制剂.
- 它是针对具有MET突变的非小细胞肺癌 (NSCLC) 开发的.
- 对乳腺,头和胃肠道癌症进行研究.
研究的目的:
- 为了验证萨沃利提尼布在NSCLC中的疗效.
- 探索其在其他胃肠道癌症中的潜力.
主要方法:
- 临床前和临床研究的综述.
- 对肺癌,癌和胃癌疗效的分析.
- 综合疗法的评估.
主要成果:
- 萨沃利提尼布在肺癌,癌和胃癌中表现出有效性.
- 在胃癌中观察到积极的结果,特别是用dcetaxel.
- 作为MET突变NSCLC的单疗法和与EGFR抑制剂结合的有效.
结论:
- 萨沃利提尼布对具有MET突变的NSCLC有效.
- 建议在胰腺癌和其他胃肠道癌症中的潜在应用.
- 进一步研究其更广泛的应用是有必要的.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
